Olle Sangfelt

Publications
Grants
CV
Public outreach and news

Articles

Journal article: GENOME BIOLOGY. 2024;25(1):143
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
Malyukova A; Lahnalampi M; Falques-Costa T; Poeloenen P; Sipola M; Mehtonen J; Teppo S; Akopyan K; Viiliainen J; Lohi O; Hagstroem-Andersson AK; Heinaeniemi M; Sangfelt O
Article: MOLECULAR CELL. 2023;83(20):3720-3739.e8
FBXL12 degrades FANCD2 to regulate replication recovery and promote cancer cell survival under conditions of replication stress
Brunner A; Li Q; Fisicaro S; Kourtesakis A; Viiliainen J; Johansson HJ; Pandey V; Mayank AK; Lehtio J; Wohlschlegel JA; Spruck C; Rantala JK; Orre LM; Sangfelt O
Article: CANCER RESEARCH. 2022;82(24):4586-4603
Dormant SOX9-Positive Cells Facilitate MYC-Driven Recurrence of Medulloblastoma
Borgenvik A; Holmberg KO; Bolin S; Zhao M; Savov V; Rosen G; Hutter S; Garancher A; Rahmanto AS; Bergstrom T; Olsen TK; Mainwaring OJ; Sattanino D; Verbaan AD; Rusert JM; Sundstrom A; Bravo MB; Dang Y; Wenz AS; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Giraud G; Chen X; Taylor MD; Sangfelt O; Clifford SC; Schueller U; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Journal article: NEURO-ONCOLOGY. 2021;23(Supplement_6):vi220-vi221
TMOD-25. LATENT SOX9-POSITIVE CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RELAPSE
Borgenvik A; Bolin S; Savov V; Holmberg KO; Zhao M; Rosén G; Hutter S; Garancher A; Rahmanto AS; Bergström T; Mainwaring O; Sattanino D; Verbaan AD; Rusert J; Sundström A; Dang Y; Wenz A; Richardson S; Fotaki G; Giraud G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Chen X; Taylor MD; Sangfelt O; Clifford S; Schüller U; Wechsler-Reya R; Weishaupt H; Swartling F
Article: SCIENTIFIC REPORTS. 2021;11(1):11023
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Das I; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jonsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grander D; Brage SE; Johnsson P
Article: ONCOTARGET. 2021;12(11):1100-1109
Ex vivo analysis of DNA repair targeting in extreme rare cutaneous apocrine sweat gland carcinoma.
Mäkelä R; Härmä V; Badra Fajardo N; Wells G; Lygerou Z; Sangfelt O; Kononen J; Rantala JK
Article: ONCOGENE. 2021;40(13):2367-2381
A novel combination therapy targeting ubiquitin-specific protease 5 in MYCN-driven neuroblastoma
Cheung BB; Kleynhans A; Mittra R; Kim PY; Holien JK; Nagy Z; Ciampa OC; Seneviratne JA; Mayoh C; Raipuria M; Gadde S; Massudi H; Wong IPL; Tan O; Gong A; Suryano A; Diakiw SM; Liu B; Arndt GM; Liu T; Kumar N; Sangfelt O; Zhu S; Norris MD; Haber M; Carter DR; Parker MW; Marshall GM
Article: CELL. 2021;184(2):352-369.e23
FBXO44 promotes DNA replication-coupled repetitive element silencing in cancer cells
Shen JZ; Qiu Z; Wu Q; Finlay D; Garcia G; Sun D; Rantala J; Barshop W; Hope JL; Gimple RC; Sangfelt O; Bradley LM; Wohlschlegel J; Rich JN; Spruck C
Article: SCIENTIFIC REPORTS. 2020;10(1):22334
K63-linked ubiquitylation induces global sequestration of mitochondria
Richard TJC; Herzog LK; Vornberger J; Rahmanto AS; Sangfelt O; Salomons FA; Dantuma NP
Journal article: NEURO-ONCOLOGY. 2020;22(Supplement_3):iii400
MBRS-10. QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
Bolin S; Savov V; Borgenvik A; Rosén G; Olausson KH; Zhao M; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Čančer M; Jernberg-Wiklund H; Ramaswamy V; Chen X; Taylor MD; Sangfelt O; Schüller U; Clifford SC; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Article: GENOME MEDICINE. 2020;12(1):99
Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1-positive pediatric leukemia identifies drug-targetable transcription factor activities
Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Makinen A; Laukkanen S; Makinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lonnberg T; Lohi O; Heinaniemi M
Article: NEOPLASIA: AN INTERNATIONAL JOURNAL FOR ONCOLOGY RESEARCH. 2020;22(9):390-398
Ex vivo assessment of targeted therapies in a rare metastatic epithelial-myoepithelial carcinoma
Makela R; Arjonen A; Rahmanto AS; Harma V; Lehtio J; Kuopio T; Helleday T; Sangfelt O; Kononen J; Rantala JK
Article: ELIFE. 2020;9:e57894
PTEN and DNA-PK determine sensitivity and recovery in response to WEE1 inhibition in human breast cancer
Brunner A; Rahmanto AS; Johansson H; Franco M; Viiliainen J; Gazi M; Frings O; Fredlund E; Spruck C; Lehtio J; Rantala JK; Larsson L-G; Sangfelt O
Journal article: NEURO-ONCOLOGY. 2019;21(Supplement_2):ii108-ii109
MEDU-26. LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE
Bolin S; Savov V; Borgenvik A; Rosen G; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Olausson KH; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Ramaswamy V; Taylor M; Sangfelt O; Clifford S; Schuller U; Wechsler-Reya R; Weishaupt H; Swartling F
Journal article: NEURO-ONCOLOGY. 2018;20(suppl_6):vi276
TMOD-35. CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?
Bolin S; Savov V; Borgenvik A; Garancher A; Rosén G; Rahmanto A; Hutter S; Rusert J; Garzia L; Fotaki G; Hill RM; Dubuc AM; Remke M; aner M; Ramaswamy V; Clifford S; Sangfelt O; Schüller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
Journal article: NEURO-ONCOLOGY. 2017;19(suppl_6):vi260-vi261
TMOD-31. RARE SOX9+ CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE
Bolin S; Savov V; Borgenvik A; Garancher A; Rosén G; Rahmanto AS; Hutter S; Rusert J; Fotaki G; Hill R; Dubuc A; Remke M; Čančer M; Ramaswamy V; Clifford S; Sangfelt O; Schüller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
Article: MOLECULAR & CELLULAR ONCOLOGY. 2017;4(1):e1252871
Targeting SOX9 for degradation to inhibit chemoresistance, metastatic spread, and recurrence.
Suryo Rahmanto A; Swartling FJ; Sangfelt O
Article: EMBO JOURNAL. 2016;35(20):2192-2212
FBW7 suppression leads to SOX9 stabilization and increased malignancy in medulloblastoma
Rahmanto AS; Savov V; Brunner A; Bolin S; Weishaupt H; Malyukova A; Rosen G; Cancer M; Hutter S; Sundstrom A; Kawauchi D; Jones DTW; Spruck C; Taylor MD; Cho Y-J; Pfister SM; Kool M; Korshunov A; Swartling FJ; Sangfelt O
Article: THE FASEB JOURNAL. 2016;30(8):2860-2873
In β-actin knockouts, epigenetic reprogramming and rDNA transcription inactivation lead to growth and proliferation defects
Almuzzaini B; Sarshad AA; Rahmanto AS; Hansson ML; Von Euler A; Sangfelt O; Visa N; Farrants A-KO; Percipalle P
Article: BRITISH JOURNAL OF HAEMATOLOGY. 2013;162(2):210-220
TRIM13 (RFP2) downregulation decreases tumour cell growth in multiple myeloma through inhibition of NF Kappa B pathway and proteasome activity
Gatt ME; Takada K; Mani M; Lerner M; Pick M; Hideshima T; Carrasco DE; Protopopov A; Ivanova E; Sangfelt O; Grander D; Barlogie B; Shaughnessy JDJ; Anderson KC; Carrasco DR
Article: EMBO MOLECULAR MEDICINE. 2013;5(7):1067-1086
CDK-mediated activation of the SCF^FBXO28 ubiquitin ligase promotes MYC-driven transcription and tumourigenesis and predicts poor survival in breast cancer
Cepeda D; Ng H-F; Sharifi HR; Mahmoudi S; Soto Cerrato V; Fredlund E; Magnusson K; Nilsson H; Malyukova A; Rantala J; Klevebring D; Vinals F; Bhaskaran N; Zakaria SM; Rahmanto AS; Grotegut S; Nielsen ML; Szigyarto CA-K; Sun D; Lerner M; Navani S; Widschwendter M; Uhlen M; Jirstrom K; Ponten F; Wohlschlegel J; Grander D; Spruck C; Larsson L-G; Sangfelt O
Article: LEUKEMIA. 2013;27(5):1053-1062
FBXW7 regulates glucocorticoid response in T-cell acute lymphoblastic leukaemia by targeting the glucocorticoid receptor for degradation
Malyukova A; Brown S; Papa R; O'Brien R; Giles J; Trahair TN; Dalla Pozza L; Sutton R; Liu T; Haber M; Norris MD; Lock RB; Sangfelt O; Marshall GM
Article: MOLECULAR AND CELLULAR BIOLOGY. 2013;33(1):85-97
Fbw7α and Fbw7γ Collaborate To Shuttle Cyclin E1 into the Nucleolus for Multiubiquitylation
Bhaskaran N; van Drogen F; Ng H-F; Kumar R; Ekholm-Reed S; Peter M; Sangfelt O; Reed SI
Article: NATURE COMMUNICATIONS. 2012;3:976
Proteomic screen reveals Fbw7 as a modulator of the NF-κB pathway
Arabi A; Ullah K; Branca RMM; Johansson J; Bandarra D; Haneklaus M; Fu J; Aries I; Nilsson P; Den Boer ML; Pokrovskaja K; Grander D; Xiao G; Rocha S; Lehtio J; Sangfelt O
Article: CELL CYCLE. 2011;10(13):2172-2183
MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression
Lerner M; Lundgren J; Akhoondi S; Jahn A; Ng H-F; Moqadam FA; Vrielink JAFO; Agami R; Den Boer ML; Grander D; Sangfelt O
Article: BREAST CANCER RESEARCH. 2010;12(6):R105
Inactivation of FBXW7/hCDC4-β expression by promoter hypermethylation is associated with favorable prognosis in primary breast cancer
Akhoondi S; Lindstrom L; Widschwendter M; Corcoran M; Bergh J; Spruck C; Grander D; Sangfelt O
Journal article: CANCER RESEARCH. 2009;69(23_Supplement):c21
Abstract C21: A novel protein microarray analysis for the identification of protein ubiquitination in cancer
Grotegut S; Rogers J; Sangfelt O; Spruck CH
Journal article: BLOOD. 2009;114(22):1786
RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma.
Gatt ME; Mani M; Lerner M; Hideshima T; Zhang Y; Dutta J; Carrasco DE; Protopopov A; Sangfelt O; Grander D; Barlogie B; Shaughnessy JD; Anderson KC; Carrasco DR
Article: SCIENCE. 2009;326(5953):718-721
Control of Iron Homeostasis by an Iron-Regulated Ubiquitin Ligase
Vashisht AA; Zumbrennen KB; Huang X; Powers DN; Durazo A; Sun D; Bhaskaran N; Persson A; Uhlen M; Sangfelt O; Spruck C; Leibold EA; Wohlschlegel JA
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(17):2941-2952
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1
Lerner M; Harada M; Loven J; Castro J; Davis Z; Oscier D; Henriksson M; Sangfelt O; Grander D; Corcoran MM
Article: EXPERIMENTAL CELL RESEARCH. 2009;315(11):1832-1839
SCF^Fbxw7/hCdc4 targets cyclin E2 for ubiquitin-dependent proteolysis
Klotz K; Cepeda D; Tan Y; Sun D; Sangfelt O; Spruck C
Article: CANCER CELL. 2009;15(5):441-453
Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis
Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Article: CELL CYCLE. 2008;7(8):1075-1082
Both SCF^Cdc4α and SCF^Cdc4γ are required for cyclin E turnover in cell lines that do not overexpress cyclin E
Sangfelt O; Cepeda D; Malyukova A; van Drogen F; Reed SI
Article: CANCER RESEARCH. 2007;67(19):9006-9012
FBXW7/hCDC4 is a general tumor suppressor in human cancer
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dofou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Article: EXPERIMENTAL CELL RESEARCH. 2007;313(14):3141-3152
Notch signaling induces SKP2 expression and promotes reduction of p27Kip1 in T-cell acute lymphoblastic leukemia cell lines
Dohda T; Maljukova A; Liu L; Heyman M; Grander D; Brodin D; Sangfelt O; Lendahl U
Article: CANCER RESEARCH. 2007;67(12):5611-5616
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling
Malyukova A; Dohda T; von der Lehr N; Akhondi S; Corcoran M; Heyman M; Spruck C; Grander D; Lendahl U; Sangfelt O
Article: MOLECULAR BIOLOGY OF THE CELL. 2007;18(5):1670-1682
The RBCC gene RFP2 (leu5) encodes a novel transmembrane E3 ubiquitin ligase involved in ERAD
Lerner M; Corcoran M; Cepeda D; Nielsen ML; Zubarev R; Ponten F; Uhlen M; Hober S; Grander D; Sangfelt O
Article: MOLECULAR CELL. 2006;23(1):37-48
Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms
van Drogen F; Sangfelt O; Malyukova A; Matskova L; Yeh E; Means AR; Reed SI
Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 2005;25(2):63-72
The HPV-16 E7 oncogene sensitizes malignant cells to IFN-α-induced apoptosis
Thyrell L; Sangfelt O; Zhivotovsky B; Pokrovskaja K; Wang YS; Einhorn S; Grandér D
Article: HUMAN MOLECULAR GENETICS. 2004;13(23):2925-2936
Disruption of a novel ectodermal neural cortex 1 antisense gene, ENC-1AS and identification of ENC-1 overexpression in hairy cell leukemia
Hammarsund M; Lerner M; Zhu CY; Merup M; Jansson M; Gahrton G; Kluin-Nelemans H; Einhorn S; Grandér D; Sangfelt O; Corcoran M
Article: GENES CHROMOSOMES AND CANCER. 2004;40(4):285-297
DLEU2 encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse
Corcoran MM; Hammarsund M; Zhu CY; Lerner M; Kapanadze B; Wilson B; Larsson C; Forsberg L; Ibbotson RE; Stefan E; Oscier DG; Grandér D; Sangfelt O
Article: CANCER RESEARCH. 2004;64(3):795-800
Mutation of hCDC4 leads to cell cycle deregulation of cyclin E in cancer
Reed SE; Spruck CH; Sangfelt O; van Drogen F; Mueller-Holzner E; Widschwendter M; Zetterberg A; Reed SI
Article: FEBS LETTERS. 2004;556(1-3):75-80
Characterization of a novel B-CLL candidate gene -: DLEU7 -: located in the 13q14 tumor suppressor locus
Hammarsund M; Corcoran MM; Wilson W; Zhu CY; Einhorn S; Sangfelt O; Grander D
Article: GENE. 2003;321:103-112
Distinct organization of the candidate tumor suppressor gene RFP2 in human and mouse:: multiple mRNA isoforms in both species- and human-specific antisense transcript RFP2OS
Baranova A; Hammarsund M; Ivanova DV; Skoblov M; Sangfelt O; Corcoran M; Borodina T; Makeeva N; Pestova A; Tyazhelova T; Nazarenko S; Gorreta F; Alsheddi T; Schlauch K; Nikitin E; Kapanadze B; Shagin D; Poltaraus A; Vorobiev AI; Zabarovsky E; Lukianov S; Chandhoke V; Ibbotson R; Oscier D; Einhorn S; Grander D; Yankovsky N
Article: CANCER RESEARCH. 2002;62(16):4535-4539
hCDC4 gene mutations in endometrial cancer
Spruck CH; Strohmaier H; Sangfelt O; Müller HM; Hubalek M; Müller-Holzner E; Marth C; Widschwendter M; Reed SI
Article: ONCOGENE. 2002;21(8):1251-1262
Mechanisms of Interferon-alpha induced apoptosis in malignant cells
Thyrell L; Erickson S; Zhivotovsky B; Pokrovskaja K; Sangfelt O; Castro J; Einhorn S; Grandér D
Article: THE FEBS JOURNAL. 2002;269(1):29-37
Interferon-alpha inhibits Stat5 DNA-binding in IL-2 stimulated primary T-lymphocytes
Erickson S; Matikainen S; Thyrell L; Sangfelt O; Julkunen I; Einhorn S; Grandér D
Article: HUMAN GENETICS. 2001;109(5):542-550
Identification and characterization of two novel human mitochondrial elongation factor genes, hEFG2 and hEFG1, phylogenetically conserved through evolution
Hammarsund M; Wilson W; Corcoran M; Merup M; Einhorn S; Grandér D; Sangfelt O
Article: RUSSIAN JOURNAL OF GENETICS. 2001;37(11):1286-1292
The transcription map of the 13q14 region frequently deleted in B-cell chronic lymphocytic leukemia
Tyazhelova TV; Ivanov DV; Makeeva NV; Kapanadze BI; Nikitin EA; Semov AB; Sangfelt O; Grander D; Vorobiev AI; Einhorn S; Yankovsky NK; Baranova AV
Article: NATURE. 2001;413(6853):316-322
Human F-box protein hCdc4 targets cyclin E for proteolysis and is mutated in a breast cancer cell line
Strohmaier H; Spruck CH; Kaiser P; Won KA; Sangfelt O; Reed SI
Journal article: BLOOD. 2000;96(13):4313-4318
Interferon α down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells
Xu D; Erickson S; Szeps M; Gruber A; Sangfelt O; Einhorn S; Pisa P; Grandér D
Article: BLOOD. 2000;96(13):4313-4318
Interferon or down-regulates telomerase reverse transcriptase and telomerase activity in human malignant and nonmalignant hematopoietic cells
Xu DW; Erickson S; Szeps M; Gruber A; Sangfelt O; Einhorn S; Pisa P; Grandér D
Article: GENOMICS. 2000;70(3):327-334
Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia, and its homologous region on mouse chromosome 14
Kapanadze B; Makeeva N; Corcoran M; Jareborg N; Hammarsund M; Baranova A; Zabarovsky E; Vorontsova O; Merup M; Gahrton G; Jansson M; Yankovsky N; Einhorn S; Oscier D; Grandér D; Sangfelt O
Article: MOLECULAR CANCER RESEARCH. 1999;10(8):575-582
Interferon-α inhibits proliferation in human T lymphocytes by abrogation of interleukin 2-induced changes in cell cycle-regulatory proteins
Erickson S; Sangfelt O; Castro J; Heyman M; Einhorn S; Grandér D
Article: ONCOGENE. 1999;18(18):2798-2810
Molecular mechanisms underlying interferon-α-induced G0/G1 arrest:: CKI-mediated regulation of G1 Cdk-complexes and activation of pocket proteins
Sangfelt O; Erickson S; Castro J; Heiden T; Gustafsson A; Einhorn S; Grandér D
Article: JOURNAL OF INTERFERON AND CYTOKINE RESEARCH. 1998;18(9):691-695
In vivo induction of the interferon-stimulated protein 2′5′ oligoadenylate synthetase in tumor and peripheral blood cells during IFN-α treatment of metastatic melanoma
Grandér D; Sangfelt O; Skoog L; Hansson J
Article: ONCOGENE. 1998;17(5):595-602
Involvement of the Ink4 proteins p16 and p15 in T-lymphocyte senescence
Erickson S; Sangfelt O; Heyman M; Castro J; Einhorn S; Grandér D
Article: MOLECULAR CANCER RESEARCH. 1997;8(3):343-352
Induction of apoptosis and inhibition of cell growth are independent responses to interferon-alpha in hematopoietic cell lines
Sangfelt O; Erickson S; Castro J; Heiden T; Einhorn S; Grander D
Article: ONCOGENE. 1997;14(4):415-423
Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines
Sangfelt O; Erickson S; Einhorn S; Grander D
Article: INTERNATIONAL JOURNAL OF CANCER. 1996;67(1):106-112
Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma
Sangfelt O; Einhorn S; Bjorklund AC; Wiman KG; Okan I; Grander D
Article: SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY. 1996;31(6):604-611
Factors influencing the response to interferon therapy in chronic hepatitis C - Studies on viral genotype and induction of 2',5'-oligoadenylate synthetase in the liver and peripheral blood cells
Grander D; Hultcrantz R; Weiland O; Xu B; Sangfelt O; Bjorklund AC; Befrits R; Bjorkholm M; Gruber A; Kinnman N; Reichard O; Widell A; Einhorn S
Article: INTERNATIONAL JOURNAL OF CANCER. 1995;63(2):190-192
RESPONSE TO INTERFERON THERAPY IN PATIENTS WITH MULTIPLE-MYELOMA CORRELATES WITH EXPRESSION OF THE BCL-2 ONCOPROTEIN
SANGFELT O; OSTERBORG A; GRANDER D; ANDERBRING E; OST A; MELLSTEDT H; EINHORN S
Journal article: BLOOD. 1994;84(6):1942-1949
PRIMARY LEUKEMIA-CELLS RESISTANT TO ALPHA-INTERFERON IN-VITRO ARE DEFECTIVE IN THE ACTIVATION OF THE DNA-BINDING FACTOR INTERFERON-STIMULATED GENE FACTOR-3
XU B; GRANDER D; SANGFELT O; EINHORN S
Show more

All other publications

Preprint: BIORXIV. 2023
Sequential drug treatment targeting cell cycle and cell fate regulatory programs blocks non-genetic cancer evolution in acute lymphoblastic leukemia
Malyukova A; Lahnalampi M; Falqués-Costa T; Pölönen P; Sipola M; Mehtonen J; Teppo S; Viiliainen J; Lohi O; Hagström-Andersson AK; Heinäniemi M; Sangfelt O
Conference publication: BLOOD. 2022;140:11576
Mechanistic Study of Wee1 Kinase Inhibition with AZD1775 Exposes Drug Targetable Vulnerabilities in Acute BLymphoblastic Leukemia
Malyukova A; Lahnalampi M; Falques T; Polonen P; Sipola M; Mehtonen J; Teppo S; Viiliainen J; Lohi O; Hagstroem-Andersson A; Heinaniemi M; Sangfelt O
Conference publication: NEURO-ONCOLOGY. 2021;23:220-221
LATENT SOX9-POSITIVE CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA
Borgenvik A; Bolin S; Savov V; Holmberg KO; Zhao M; Rosen G; Hutter S; Garancher A; Rahmanto AS; Bergstrom T; Mainwaring O; Sattanino D; Verbaan AD; Rusert J; Sundstrom A; Dang Y; Wenz A; Richardson S; Fotaki G; Giraud G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Chen X; Taylor MD; Sangfelt O; Clifford S; Schuller U; Wechsler-Reya R; Weishaupt H; Swartling F
Conference publication: CANCER RESEARCH. 2020;80(16):2371
FBXL12 modulates Fanconi anaemia-BRCA signaling under conditions of oncogene-induced replication stress
Brunner A; Johansson H; Kourtesakis A; Rantala J; Spruck C; Wohlschlegel J; Lehtio J; Sangfelt O
Preprint: BIORXIV. 2020
Single cell characterization of B-lymphoid differentiation and leukemic cell states during chemotherapy in ETV6-RUNX1 positive pediatric leukemia identifies drug-targetable transcription factor activities
Mehtonen J; Teppo S; Lahnalampi M; Kokko A; Kaukonen R; Oksa L; Bouvy-Liivrand M; Malyukova A; Laukkanen S; Mäkinen PI; Rounioja S; Ruusuvuori P; Sangfelt O; Lund R; Lönnberg T; Lohi O; Heinäniemi M
Preprint: BIORXIV. 2020
PTENP1-AS contributes to BRAF inhibitor resistance and is associated with adverse clinical outcome in stage III melanoma
Vidarsdottir L; Azimi A; Sigvaldadottir I; Rahmanto AS; Petri A; Kauppinen S; Ingvar C; Jönsson G; Olsson H; Stolt MF; Tuominen R; Sangfelt O; Tamm KP; Hansson J; Grandér D; Brage SE; Johnsson P
Conference publication: NEURO-ONCOLOGY. 2020;22:400
QUIESCENT SOX9-POSITIVE CELLS BEHIND MYC DRIVEN MEDULLOBLASTOMA RECURRENCE
Bolin S; Savov V; Borgenvik A; Rosen G; Olausson KH; Zhao M; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill RM; Dubuc AM; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Ramaswamy V; Chen X; Taylor MD; Sangfelt O; Schueller U; Clifford SC; Wechsler-Reya RJ; Weishaupt H; Swartling FJ
Conference publication: NEURO-ONCOLOGY. 2019;21:108-109
LATENT SOX9-POSITIVE CELLS RESPONSIBLE FOR MYC-DRIVEN MEDULIOBEASTOMA RECURRENCE
Bolin S; Savov V; Borgenvik A; Rosen G; Garancher A; Rahmanto AS; Hutter S; Mainwaring O; Olausson KH; Rusert J; Sundstrom A; Richardson S; Fotaki G; Hill R; Dubuc A; Kalushkova A; Remke M; Cancer M; Jernberg-Wiklund H; Ramaswamy V; Taylor M; Sangfelt O; Clifford S; Schuller U; Wechsler-Reya R; Weishaupt H; Swartling F
Conference publication: NEURO-ONCOLOGY. 2018;20:276
CAN RARE SOX9-POSITIVE CELLS INCITE MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE?
Bolin S; Savov V; Borgenvik A; Garancher A; Rosen G; Rahmanto A; Hutter S; Rusert J; Garzia L; Fotaki G; Hill RM; Dubuc AM; Remke M; Aner M; Ramaswamy V; Clifford S; Sangfelt O; Schueller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
Corrigendum: CANCER CELL. 2017;31(5):724-726
Ablation of Key Oncogenic Pathways by RITA-Reactivated p53 Is Required for Efficient Apoptosis (vol 15, pg 441, 2009)
Grinkevich VV; Nikulenkov F; Shi Y; Enge M; Bao W; Maljukova A; Gluch A; Kel A; Sangfelt O; Selivanova G
Conference publication: NEURO-ONCOLOGY. 2017;19:260-261
RARE SOX9+CELLS BEHIND MYC-DRIVEN MEDULLOBLASTOMA RECURRENCE
Bolin S; Savov V; Borgenvik A; Garancher A; Rosen G; Rahmanto AS; Hutter S; Rusert J; Fotaki G; Hill R; Dubuc A; Remke M; Cancer M; Ramaswamy V; Clifford S; Sangfelt O; Schueller U; Taylor M; Wechsler-Reya R; Weishaupt H; Swartling F
Review: ONCOGENE. 2014;33(39):4709-4721
Oncoprotein stabilization in brain tumors
Hede S-M; Savov V; Weishaupt H; Sangfelt O; Swartling FJ
Conference publication: BLOOD. 2009;114(22):710
RFP2 Modulates 20S Proteasome Activity, NF Kappa B Activation, and Tumor Cell Growth in Multiple Myeloma.
Gatt ME; Mani M; Lerner M; Hideshima T; Zhang Y; Dutta J; Carrasco DE; Protopopov A; Sangfelt O; Grander D; Barlogie B; Shaughnessy JDJ; Anderson KC; Carrasco DR
Review: CANCER LETTERS. 2008;271(1):1-12
The Fbxw7/hCdc4 tumor suppressor in human cancer
Tan Y; Sangfelt O; Spruck C
Corrigendum: CANCER RESEARCH. 2008;68(6):2051
The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling (vol 67, pg 5611, 2007)
Malyukova A; Dohda T; von der Lehr N; Akhoondi S; Corcoran M; Heyman M; Spruck C; Grander D; Lendahl U; Sangfelt O
Corrigendum: CANCER RESEARCH. 2008;68(4):1245
The FBXW7 gene is mutated in a variety of human tumors (vol 67, pg 9006, 2007)
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Capeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Book chapter: HORMONAL CARCINOGENESIS IV. 2005;p. 98-105
Deregulation of Cyclin E and Genomic Instability
Spruck CH; Smith APL; Reed SE; Sangfelt O; Keck J; Strohmaier H; Méndez J; Widschwendter M; Stillman B; Zetterberg A; Reed SI
Meeting abstract: BLOOD. 2004;104(11):430A
Disruption of the HEXB/ENC-1 antisense gene and identification of elevated ENC-1 expression in patients with Hairy Cell Leukemia
Lerner M; Hammarsund M; Sangfelt O; Zhu CY; Merup M; Jansson M; Gahrton G; Kluin-Nelemans H; Einhorn S; Grander D; Corcoran M
Meeting abstract: BLOOD. 2004;104(11):431A
DLEU2, located within the CLL 13q14 deletion locus, encodes an antisense RNA for the putative bicistronic RFP2/LEU5 gene in humans and mouse
Corcoran MM; Hammarsund M; Zhu CY; Lerner M; Kapanadze B; Larsson C; Forsberg L; Ibbotson RE; Einhorn S; Oscier DG; Grander D; Sangfelt O
Review: MEDICAL ONCOLOGY. 2001;18(1):3-14
Apoptosis and cell growth inhibition as antitumor effector functions of interferons
Sangfelt O; Strander H
Review: FRONTIERS IN BIOSCIENCE - LANDMARK. 2000;5:D479-D487
Mechanisms of interferon-induced cell cycle arrest
Sangfelt O; Erickson S; Grandér D
Conference publication: BLOOD. 2000;96(11):703A
Comparative sequence analysis of a region on human chromosome 13q14, frequently deleted in B-cell chronic lymphocytic leukemia and its homologous region on mouse chromosome 14.
Kapanadze B; Makeevaa N; Corcoran MM; Jareborg N; Hammarsund M; Baranova A; Zabarovsky E; Vorontcova O; Merup M; Jansson O; Gahrton G; Oscier DG; Einhorn S; Grander D; Sangfelt O
Conference publication: BLOOD. 2000;96(11):702A-703A
Characterisation of a candidate tumor suppressor gene LEU2B located at 13q14.3 in chronic lymphocytic leukemia.
Corcoran MM; Sangfelt O; Kapanadze B; Makeevaa N; Ibbotson RE; Baranova A; Zabarovsky E; Merup M; Jansson O; Gahrton G; Einhorn S; Grander D; Oscier DG
Conference publication: BLOOD. 1999;94(10):148B
Interferon-α inhibits T-lymphocyte proliferation and selectively interferes with the IL-2 signalling pathway.
Grandér D; Erickson S; Matikainen S; Sangfelt O; Julkunen I; Einhorn S
Thesis / dissertation: 1998
Effects of interferon on cellular proliferation and apoptosis
Sangfelt, Olle
Review: EUROPEAN JOURNAL OF HAEMATOLOGY. 1997;59(3):129-135
How does interferon exert its cell growth inhibitory effect?
Grander D; Sangfelt O; Erickson S
Conference publication: EUROPEAN JOURNAL OF CELL BIOLOGY. 1997;72:69
IFN-alpha prevents IL-2 mediated elimination of p27 and proliferation in T-lymphocytes.
Erickson S; Sangfelt O; Heyman M; Castro J; Einhorn S; Grander D
Show more

Grants

Exploiting the Ubiquitin System to Target the "Undruggable" Cancer Proteome
Swedish Research Council
1 January 2024 - 31 December 2026
Ubiquitin ligases as targets for immunotherapy treatment in intractable childhood cancer
Barncancerfonden
1 January 2022 - 31 December 2022
Ubiquitin Ligases as molecular targets and novel cancer markers
Swedish Research Council
1 January 2021 - 31 December 2023
Analyzes of enzymes that control vital signaling pathways in cancer cells and targeted therapy against these support systems in cancer tumors.
Swedish Cancer Society
1 January 2018
Analyzes of enzymes that control vital signaling pathways in cancer cells and targeted therapy against these support systems in cancer tumors.
Swedish Cancer Society
1 January 2017
Analyzes of enzymes that control the degradation of important cancer proteins.
Swedish Cancer Society
1 January 2016
SCF E3 ubiquitin ligases as novel anticancer targets
Swedish Research Council
1 January 2015 - 31 December 2018
Analyzes of enzymes that control the degradation of important cancer proteins.
Swedish Cancer Society
1 January 2015
Analyzes of enzymes that control the degradation of important cancer proteins.
Swedish Cancer Society
1 January 2014
F-box proteins as novel cancer drug targets
Swedish Research Council
1 January 2012 - 31 December 2014
F-box proteins as novel cancer drug targets
Swedish Research Council
1 January 2009 - 31 December 2011
A high resolution mass spectrometer with multiple ionization functionality for research in metabolomics and proteomics
Swedish Research Council
1 January 2009 - 31 October 2014

Employments

Principal Researcher, Department of Cell and Molecular Biology, Karolinska Institutet, 2022-

Degrees and Education

Docent, Karolinska Institutet, 2011
Doctor Of Philosophy, Department of Oncology-Pathology, Karolinska Institutet, 1998

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI